Managing Severe Asthma in Australia – the Epithelial Era

Research Review CPD-Accredited E-Learning Module

Begin

Managing Severe Asthma in Australia – the Epithelial Era

This Research Review E-Learning Module is intended for Australian Health Professionals and is based on the Research Review Educational Series publication ‘Managing Severe Asthma in Australia – the Epithelial Era’.

This educational series aimed to provide clinicians with an up-to-date overview of severe asthma management, focusing on the heterogeneity of the disease, role of biomarkers, and latest treatment options, including the novel biologic tezepelumab (TEZSPIRE®). This E-Learning Module is a simple multi-choice quiz to measure understanding of the Educational Series and to provide certification for the purposes of claiming CPD points 

Before starting the module please read the Research Review Educational Series, accessed through the link below:

CLICK HERE
to access the quiz source material
Educational Series - Managing Severe Asthma in Australia – the Epithelial Era

The PDF through the link above can be viewed on screen, saved and printed.

This E-Learning Module covers:

  • The heterogeneity of severe asthma, including phenotypes and endotypes
  • The role and interpretation of biomarkers in severe asthma management
  • Mechanisms of action and clinical evidence for biologic therapies, with a focus on tezepelumab
  • Practical guidance for optimising severe asthma management, including personalised reviews and therapy adjustment
  • Strategies to reduce exacerbation burden and improve patient outcomes in the Australian context

Learning outcomes

After completing this module, you should have an improved understanding of:

  • Recognise the diverse phenotypes and endotypes of severe asthma and their clinical implications
  • Interpret and apply biomarker data to guide personalised severe asthma management
  • Understand the mechanism, efficacy, and safety profile of tezepelumab and its place in therapy
  • Implement evidence-based strategies to optimise treatment and reduce exacerbations in severe asthma
  • Facilitate shared decision-making and timely referral for specialist assessment in patients with uncontrolled asthma

Participants are expected to answer a minimum of 70% of questions correctly to achieve the level required to receive CPD certification.  

Contributing experts

Expert commentary is provided by:
Clinical Nurse Consultant Brooke Kyle, Sir Charles Gairdner Hospital, WA. 
Clinical Professor John Blakey, Head of Department of Respiratory Medicine, Sir Charles Gairdner Hospital, WA.

Clinical Nurse Consultant Brooke Kyle and Clinical Professor John Blakey have reviewed and approved the questions included in this module.

Accreditation

RACP (Royal Australasian College of Physicians) MyCPD participants can claim the time spent completing Research Review modules as CPD in the online MyCPD program. Please contact MyCPD@racp.edu.au for any assistance. Please CLICK HERE to download CPD Information.

Nursing and Midwifery Board of Australia (NMBA) Completing e-Learning modules may be considered a self-directed activity set out in the NMBA Registration Standard: Continuing Professional Development. Nurses and midwives are required to complete a minimum number of CPD hours directly relevant to their context of practice. One hour of active learning will equal one hour of CPD. For more information go to The Nursing and Midwifery Board of Australia (NMBA) CPD page. Please CLICK HERE to download more info.

References

  1. AstraZeneca Australia Pty Ltd. Australian Product Information – Tezepelumab (TEZSPIRE®). 2025.
  2. Panettieri R Jr, et al. J Asthma Allergy. 2024;17:219–236. doi:10.2147/JAA.S342391.
  3. Australian Institute of Health and Welfare. Asthma. Canberra: AIHW; 2024. Available from: https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma. [Accessed June 2025].
  4. To T, et al. BMC Public Health. 2012;12:204. doi:10.1186/1471-2458-12-204.
  5. Hancock KL, et al. Pragmat Obs Res. 2022;13:43–58. doi:10.2147/POR.S360044.
  6. McDonald VM, et al. Respirology. 2019;24:37–47. doi:10.1111/resp.13389.
  7. Fouka E, et al. Front Med (Lausanne). 2022;9:992565. doi:10.3389/fmed.2022.992565.
  8. Ricciardolo FLM, et al. Eur Respir Rev. 2023;32(168):220201. doi:10.1183/16000617.0201-2022.
  9. Caminati M, et al. Respir Res. 2024;25(1):367. doi:10.1186/s12931-024-02998-6.
  10. Brightling CE, et al. Eur Respir Rev. 2024;33(174):240221. doi:10.1183/16000617.0221-2024.
  11. Varricchi G, et al. Eur Respir J. 2024;63(4):2301619. doi:10.1183/13993003.01619-2023.
  12. Wang E, et al. [published correction appears in 2021;160(5):1989. doi:10.1016/j.chest.2021.09.030]. Chest. 2020;157(4):790–804. doi:10.1016/j.chest.2019.10.053.
  13. Ryan D, et al. J Allergy Clin Immunol Pract. 2021;9:1612–1623. doi:10.1016/j.jaip.2020.11.053.
  14. Jenkins CR, et al. Med J Aust. 2023;219(2):49–52. doi:10.5694/mja2.52000.
  15. Semprini R, et al. Thorax. 2019;74(1):95–98. doi:10.1136/thoraxjnl-2018-211657.
  16. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024. Available from: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. [Accessed June 2025].
  17. Denton E, et al. [published correction appears in J Allergy Clin Immunol Pract. 2021;9(11):4182. doi: 10.1016/j.jaip.2021.09.006]. J Allergy Clin Immunol Pract. 2021;9(7):2680–2688.e7. doi:10.1016/j.jaip.2021.02.059.
  18. Kupczyk M, et al. Allergy. 2014;69(9):1198–1204. doi:10.1111/all.12445.
  19. Australasian Society of Clinical Immunology and Allergy. Biologics in Severe Asthma- Change in PBS Criteria – October 2024. Available at: https://www.allergy.org.au/about-ascia/info-updates/biologics-in-severe-asthma-change-in-pbs-criteria-1-october-2024. [Accessed June 2025].
  20. Services Australia. Severe asthma - adolescent and adult - initial or recommencement after 12 months break authority application form (PB075). Available from: https://www.servicesaustralia.gov.au/pb075. [Accessed June 2025].
  21. Novartis Pharmaceuticals Australia Pty Ltd. Australian Product Information –Omalizumab (XOLAIR®). 2023.
  22. GlaxoSmithKline Australia Pty Ltd. Australian Product Information – Mepolizumab (NUCALA®). 2022.
  23. Sanofi-Aventis Australia Pty Ltd. Australian Product Information – Dupilumab (DUPIXENT®). 2023.
  24. AstraZeneca Australia Pty Ltd. Australian Product Information – Benralizumab (FASENRA®). 2023.
  25. Upham JW, Chung LP. Med J Aust. 2018;209(S2):S22–S27. doi:10.5694/mja18.00175.
  26. Chandrasekara S, Wark P. Aust Prescr. 2024;47:36–42. doi:10.18773/austprescr.2024.015.
  27. Jackson DJ, et al. [published correction appears in 2024;403(10432):1140. doi: 10.1016/S0140-6736(24)00544-0]. Lancet. 2024;403(10423):271–281. doi:10.1016/S0140-6736(23)02284-5.
  28. Corren J, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma: apooled analysis of the phase 2b PATHWAY and phase 3 NAVIGATOR studies. Presentedat: American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.Phoenix, AZ, USA; 2022.
  29. Corren J, et al. Clin Exp Allergy. 2023;53(4):417–428. doi:10.1111/cea.14256.
  30. Corren J, et al. Am J Respir Crit Care Med. 2023;208(1):13–24. doi:10.1164/rccm.202210-2005OC.
  31. Wechsler ME, et al. [published correction appears in Lancet Respir Med. 202210(7):e72.doi: 10.1016/S2213-2600(22)00128-X]. Lancet Respir Med. 2022;10(7):650–660.doi:10.1016/S2213-2600(21)00537-3.
  32. Diver S, et al. [published correction appears in Lancet Respir Med. 2021;9(11):e106.doi: 10.1016/S2213-2600(21)00446-X]. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5.
  33. Crowther L, et al. [abstract]. Am J Respir Crit Care Med 2024;209:A5382.
  34. Miralles-López JC, et al. Allergol Immunopathol (Madr). 2025;53(2):163–173.doi:10.15586/aei.v53i2.1326.
  35. Akuthota P, et al. Substantial reduction in asthma exacerbations in patients with severe asthma with or without clinically relevant perennial allergy after 6 months ofrezepelumab use: Interim results from the Phase 4 PASSAGE Study. Presented at:2025 AAAAI/WAO Joint Congress. San Diego, CA, USA;28 February–03 March 2025.Abstract 711.
  36. Roxas C, et al. Thorax. 2024;79:A281.
  37. Corren J, et al. [published correction appears in N Engl J Med. 2019;380(21):2082.doi: 10.1056/NEJMx180026]. N Engl J Med. 2017;377(10):936–946. doi:10.1056/NEJMoa1704064.
  38. Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975.
  39. Menzies-Gow A, et al. [published correction appears in Lancet Respir Med. 2023;11(3):e25. doi: 10.1016/S2213-2600(23)00048-6]. Lancet Respir Med. 2023;11(5):425–438. doi:10.1016/S2213-2600(22)00492-1.
  40. Emergency Care Institute – Agency for Clinical Innovation. Asthma management. Available at: https://aci.health.nsw.gov.au/networks/eci/clinical/tools/respiratory/asthma/asthma-management. [Accessed June 2025].
‹Previous Next›